Flow cytometric analysis of Human CD40 expression on human PBMCs (human peripheral blood mononuclear cells). Human PBMCs were stained with Brilliant Violet 421™ Mouse Anti-Human CD19 Antibody and either PE Human IgG1, κ Isotype Control (left panel) or SDT PE Human Anti-Human CD40 Antibody (right panel) at 2 μl/test. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
PE Human Anti-Human CD40 Antibody (ABBV-323)
PE Human Anti-Human CD40 Antibody (ABBV-323)
Price:
Regular price
$130 USD
Regular price
Sale price
$130 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Human |
| Antigen | CD40 |
| Location | Cell membrane |
| Accession | P25942 |
| Clone Number | ABBV-323 |
| Antibody Type | Recombinant mAb |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human PBMC |
| Purification | Protein A |
| Concentration | 0.1 mg/ml |
| Conjugation | PE |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 2μl per million cells in 100μl volume | Hu |
Background
CD40, also known as TNFRSF5 or Bp50, is a 48 kDa type I membrane glycoprotein belonging to the tumor necrosis factor receptor superfamily. It is widely expressed on various immune cells, including B cells, dendritic cells, and macrophages. The interaction between CD40 and its ligand, CD40L, is crucial for immune cell activation and regulation. Structurally, CD40 consists of a 62 amino acid cytoplasmic tail, a 22 amino acid transmembrane domain, and a 173 amino acid extracellular domain. This co-stimulatory protein plays a key role in B cell activation, proliferation, and differentiation, and is also involved in immune responses against infections and tumors. Due to its significant role in the immune system, CD40 has become an important therapeutic target, with various agonistic and antagonistic antibodies being developed to modulate its activity.
Picture
Picture
FC
